Page 9 - Binding Affinity News Today

Researchers use molecular docking to screen phytocompounds and evaluate their binding affinity with SARS-CoV-2.

Researchers identify potential ACE2 inhibitors through a virtual screening protocol.

A new Cells review discusses the factors that affect the function of the SARS-CoV-2 S protein and provides theoretical limits of this viral protein.

Researchers presented a technique called rapid in vitro inhibition assay (RIVIA), whereby potential SARS-CoV-2 antibody and nanobody candidates can be rapidly screened.

Researchers engineered a mutant ACE2 decoy that effectively protected human lung epithelia from SARS-CoV-2 infection by competitively binding to its spike protein.

Researchers evaluated the synergistic activity of drugs acting against non-structural protein 1 of SARS-CoV-2 to decrease the viral infectivity.

A recent study published in the iScience Journal assessed the influence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on coronavirus disease 2019 (COVID-19) infectivity and viral neutralization.

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.

Researchers developed a novel computational model to predict the binding affinity between the hACE2 receptor and the RBD of S protein of SARS-CoV-2.

In a new study, scientists evaluated the cycle threshold values from 1,297 COVID-19-positive saliva samples obtained at a testing lab in the USA.